Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $5.6 million.

  • Arcutis Biotherapeutics' Change in Accured Expenses fell 4494.27% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.8 million, marking a year-over-year increase of 6059.68%. This contributed to the annual value of $32.0 million for FY2024, which is 47263.14% up from last year.
  • Arcutis Biotherapeutics' Change in Accured Expenses amounted to $5.6 million in Q3 2025, which was down 4494.27% from $21.2 million recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Change in Accured Expenses peaked at $21.2 million during Q2 2025, and registered a low of -$5.5 million during Q1 2022.
  • Its 5-year average for Change in Accured Expenses is $4.0 million, with a median of $3.4 million in 2021.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Change in Accured Expenses skyrocketed by 171117.24% in 2021 and then tumbled by 23476.54% in 2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Change in Accured Expenses (Quarter) stood at $11.7 million in 2021, then crashed by 94.73% to $616000.0 in 2022, then surged by 860.55% to $5.9 million in 2023, then surged by 122.8% to $13.2 million in 2024, then plummeted by 57.72% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q3 2025, $21.2 million for Q2 2025, and -$214000.0 during Q1 2025.